Navigation Links
Pharmacyclics Reports Second Quarter 2013 Results
Date:7/31/2013

Recent Developments & HighlightsTwo New England Journal of Medicine Publications
In June 2013, The New England Journal of Medicine (NEJM) published results from two Phase II studies of ibrutinib:  PCYC 1104-CA, a Phase II study evaluating  the safety and efficacy of ibrutinib monotherapy in patients with relapsed/refractory MCL; and PCYC 1102-CA, a Phase Ib/II study examining the safety and efficacy of ibrutinib monotherapy for the treatment of patients with relapsed/refractory CLL/ SLL, some of whom had deletion of part of chromosome 17 (del 17p). These data suggested ibrutinib may be effective and generally well-tolerated in patients with relapsed/refractory MCL and in patients with relapsed/refractory CLL/SLL. Both studies were originally presented at the annual meeting of the American Society of Hematology (ASH) in December 2012. Updated results from PCYC 1104-CA were presented at the European Hematology Association (EHA) Annual Meeting in June 2013.

Conferences and Presentations in June 2013
In June, Pharmacyclics and its collaborators presented 5 oral and 6 poster presentations on ibrutinib at three annual conferences: American Society of Clinical Oncology (ASCO), EHA, and the International Conference on Malignant Lymphoma (ICML).  These conferences showcased updated and expanded data in high risk CLL, relapsed or refractory MCL, and relapsed or refractory diffuse large B-cell lymphoma (DLBCL).  Also at these conferences ibrutinib data in two new areas were presented: Waldenstrom's Macroglobulinemia (WM) and frontline DLBCL in combination with R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone). All oral presentations made at these conferences have been filed in Form 8-K's with the SEC.

Selected Clinical Trials Initiated with Ibrutinib Over the Last 18 MonthsCLL/SLL

  • RESONATE™ (PCYC-1112) Phase III study of ibrutinib versus ofatumumab in patients wi
    '/>"/>

  • SOURCE Pharmacyclics, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17

    Related medicine technology :

    1. Pharmacyclics Announces Date of Financial Results for Second Quarter Ended June 30, 2013 and Conference Call
    2. Pharmacyclics Reports First Quarter 2013 Results
    3. Pharmacyclics Announces Date of Financial Results for Three Months Ended March 31, 2013 and Conference Call
    4. Pharmacyclics Triggers Fourth Milestone Payment for Enrollment of 5th Patient in Frontline Phase III CLL Study
    5. Pharmacyclics Announces Third Breakthrough Therapy Designation for Ibrutinib from the U.S. Food and Drug Administration
    6. Pharmacyclics, Inc. Prices Public Offering of Common Stock
    7. Pharmacyclics, Inc. Announces Proposed Public Offering of Common Stock
    8. Pharmacyclics First to Announce Breakthrough Therapy Designation in Oncology from the U.S. Food and Drug Administration
    9. Pharmacyclics Announces Date of Financial Results for Three and Six Months Ended December 31, 2012 and Conference Call
    10. Pharmacyclics Reports Fourth Quarter and Full Year Fiscal 2012 Financial Results and Recent Developments
    11. Pharmacyclics Announces Oral Presentations of Ibrutinib (PCI-32765) at the 17th Congress of the European Hematology Association
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/29/2014)... VIENNA , July 29, 2014 ... Vienna, Austria will present data from a ... that aims to slow or stop Parkinson,s disease progression. ... a $ 1.5 million grant and will discuss the impact ... community. When:   Thursday, July 31, 2014 ...
    (Date:7/29/2014)... 2014   Abide Therapeutics announced today ... its board of directors. Thornberry was previously senior ... for Merck & Co. Inc., where she led ... in diabetes, osteoporosis, fertility and contraception. Thornberry, a ... that resulted in the discovery of Januvia TM ...
    (Date:7/29/2014)... Today, Frost & Sullivan recognizes Validic ... Practices Award for Customer Value Leadership. The Validic ... connects digital health application developers, medical devices and ... prevention and wellness companies, population health management companies ... Frost & Sullivan presents this award to a ...
    Breaking Medicine Technology:Reminder/Media Advisory/AFFiRiS AG Presents Early Clinical Data on a First-of-its-Kind Parkinson's Disease Vaccine 2Abide Therapeutics Appoints Nancy Thornberry to Board of Directors 2Abide Therapeutics Appoints Nancy Thornberry to Board of Directors 3Frost & Sullivan Commends Validic for Delivering Superior Customer Value through its mHealth Interoperability Technology Platform 2Frost & Sullivan Commends Validic for Delivering Superior Customer Value through its mHealth Interoperability Technology Platform 3Frost & Sullivan Commends Validic for Delivering Superior Customer Value through its mHealth Interoperability Technology Platform 4
    (Date:7/29/2014)... JACKSONVILLE, Fla. Imagine a future in which a new ... patient,s own cellular material, or a day when an injection ... in the brain, nerves or other tissues. , MULTIMEDIA ALERT: ... talking about the gift and regenerative medicine, visit the ... is no longer science fiction, and a substantial gift ...
    (Date:7/29/2014)... (PRWEB) July 29, 2014 PharmaSphere: ... Biosimilars Market report is an essential source of ... Using detailed company data, financial analysis, corporate strategy, ... of the current and future growth drivers of ... regulatory frameworks under which biosimilars are currently reviewed ...
    (Date:7/29/2014)... Collierville, TN (PRWEB) July 29, 2014 ... to the reimbursement model of all hospitals. Studies show ... tsunami.[1] One simple, easy, low cost tool that ... organizational performance by 20 to 25%. , Their secret? ... to one anther at the end of an operational ...
    (Date:7/29/2014)... lead to a more streamlined process for obtaining stem cells, ... replacement tissue for failing body parts, according to UC San ... of Cell . , The work builds on a ... state in which they again have the potential to become ... process may soon increase thanks to the scientists, identification of ...
    (Date:7/29/2014)... Rock, AR (PRWEB) July 29, 2014 ... , a resolution declaring the week of October 12-18, ... value of case management in improving healthcare outcomes for ... (D-AR) and Senator John Boozman (R-AR), with support by ... Case Management Association to honor case management professionals for ...
    Breaking Medicine News(10 mins):Health News:Bacardis make gift to significantly advance Mayo Clinic's regenerative medicine research 2Health News:Bacardis make gift to significantly advance Mayo Clinic's regenerative medicine research 3Health News:Bacardis make gift to significantly advance Mayo Clinic's regenerative medicine research 4Health News:World Biosimilars Market Value Exceed $262 Billion by 2019 Says a New Report Available at MarketOptimizer.org 2Health News:World Biosimilars Market Value Exceed $262 Billion by 2019 Says a New Report Available at MarketOptimizer.org 3Health News:World Biosimilars Market Value Exceed $262 Billion by 2019 Says a New Report Available at MarketOptimizer.org 4Health News:One Brilliant Economic Survival Tool You Can Steal from the World's Best Hospitals 2Health News:One Brilliant Economic Survival Tool You Can Steal from the World's Best Hospitals 3Health News:Stem cell advance may increase efficiency of tissue regeneration 2Health News:Stem cell advance may increase efficiency of tissue regeneration 3Health News:CMSA Supports National Case Management Week Resolution Introduced in US Senate 2
    ... , ASHBURN, Va., ... intelligent data capture and enterprise search solutions , ... Lyon France, has selected the company,s Brainware Distiller(TM) solution to ... across 150 countries and processes hundreds of thousands of invoices ...
    ... ... authors such as Jack Canfield, Dr. Joe Vitale & Marci Shimoff, Jennifer ... who entertains, educates and enlightens audiences worldwide with her highly anticipated book ... weight loss success story who has become one of the world,s most ...
    ... In the ... more options, according to Dr. Geoffrey Westrich, co-director of joint replacement research at Hospital for ... ... revolutionized the way doctors perform hip replacement and knee replacement surgery to relieve severe arthritis ...
    ... leave poses a significant barrier, experts say , SUNDAY, ... of American moms start their infants on human milk, ... months of life, let alone an entire year. ... can prove difficult for new moms, but California researchers ...
    ... experts say , FRIDAY, Dec. 25 (HealthDay News) -- Between ... and preparing your home for out-of-town guests, the holiday season ... to run high as they put pressure on themselves to ... of children. , "During the holidays, our lives become ...
    ... Scientists identify substances similar to those in pot that increase ... -- New research sheds some light on the "munchies" -- ... of food. , THC, the active ingredient in marijuana, is ... the brain and body and enhance the perception of sweet ...
    Cached Medicine News:Health News:bioMerieux Selects Brainware to Automate Accounts Payable 2Health News:bioMerieux Selects Brainware to Automate Accounts Payable 3Health News:Fitness Celebrity Jennifer Nicole Lee Reveals her Revolutionary Weight Loss Principles in 'The Mind, Body, and Soul Diet' Book 2Health News:Fitness Celebrity Jennifer Nicole Lee Reveals her Revolutionary Weight Loss Principles in 'The Mind, Body, and Soul Diet' Book 3Health News:Fitness Celebrity Jennifer Nicole Lee Reveals her Revolutionary Weight Loss Principles in 'The Mind, Body, and Soul Diet' Book 4Health News:Medical Advances Revolutionize Hip Replacement and Knee Replacement 2Health News:Medical Advances Revolutionize Hip Replacement and Knee Replacement 3Health News:Many Women Quit Breast-Feeding Early 2Health News:Many Women Quit Breast-Feeding Early 3Health News:Don't Invite Holiday Stress Into Your Home 2
    ... Finnpipette Focus from Thermo Labsystems ... ergonomics with uncompromising performance. ... offers a custom fit for ... shorter tip cones allow easier ...
    2L...
    Pipetman F is a fixed-volume, air-displacement pipette. Thirteen robust models cover a large volume range from 2 L to 1000 L, with Gilsons legendary accuracy and precision....
    ... Series 2000 Pipette is a synonym for ... and robust design, and superior operating comfort. ... operate the measuring stroke and blow-out as ... "pipette/tip" system ensures utmost accuracy and precision. ...
    Medicine Products: